research Gonadal Dysgenesis: Associations between Clinical Features and Sex of Rearing.
Gonadal biopsy is the best method to diagnose gonadal dysgenesis.
Search
for
Sort by
Research
210-240 / 1000+ results 
research How storage post sampling influences the stability of sebum when used for mass spectrometry metabolomics analysis?
Sebum samples remain stable under various storage conditions, making them suitable for remote and at-home testing.
research Female pattern hair loss in men: A distinct clinical variant of androgenetic alopecia
Men can experience female pattern hair loss, needing different treatments.
research SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth
Enzyme booster SULT1A1 greatly enhances hair regrowth with minoxidil.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Treatment of female pattern hair loss with oral antiandrogens
Oral antiandrogens effectively treat female hair loss, with better results in higher hair loss grades.
research Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02
Frontal fibrosing alopecia is linked to four genetic areas, especially the HLA-B*07:02 allele.
research Management of primary cicatricial alopecias: options for treatment
There are many treatments for permanent hair loss disorders, but their effectiveness varies and there's no clear best option.
research Treatment of alopecia areata: An Australian expert consensus statement
Alopecia areata treatment varies, with no optimal method established yet.
research A review of the treatment of male pattern hair loss
Finasteride and minoxidil work best together for hair loss.
research Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial
Oral minoxidil and topical minoxidil 5% both effectively improve female-pattern hair loss with safe side effects.
research Systemic treatments for alopecia areata: A systematic review
No systemic treatment for alopecia areata has strong evidence of effectiveness.
research 5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia
5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
research Androgen receptor genetic variant predicts COVID‐19 disease severity: a prospective longitudinal study of hospitalized COVID‐19 male patients
A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Age-Dependent Associations between Androgenetic Alopecia and Prostate Cancer Risk
Early balding at 40 increases prostate cancer risk.
research Antiandrogen therapy for androgenetic alopecia
Antiandrogen therapy helps treat genetic hair loss.
research Utility of azathioprine, methotrexate and cyclosporine as steroid‐sparing agents in chronic alopecia areata: a retrospective study of continuation rates in 138 patients
Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.
research Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes
Tretinoin boosts minoxidil's effect on hair loss by increasing enzyme activity.
research Global expression profile and global genome methylation signatures in male patients with androgenetic alopecia
Differences in gene expression and methylation patterns found in AGA patients suggest potential targets for future treatments.
research Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations
Minoxidil can treat hair loss with topical, oral, and sublingual options, offering personalized choices.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research The Alopecia Areata Severity and Morbidity Index (ASAMI) Study
Alopecia areata severity is influenced by factors like long disease duration, relapses, treatment response, and mental health, leading to the creation of a new severity measurement tool.
research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
research Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
New medications could improve treatment for severe alopecia areata in Australia.
research Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Med Check
Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.